| UHC UMR Medical and Drug | Evenity® (Romosozumab-Aqqg) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Ophthalmologic Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Benlysta® (Belimumab) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Evenity® (Romosozumab-Aqqg) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Ophthalmologic Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Surest Medical and Drug | Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy | 2025-12-01 |